Healthcare / Medical Instruments & SuppliesJakarta
$206.00
+28.00 (+13.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $260.2B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.56T
P/E
14.2x
↓EV/EBITDA
9.1x
↓ROE
13.5%
↑Gross Margin
34.8%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.9%
FCF CAGR
+153.0%
FCF margin
13.5%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.06T · net income $366.95B · FCF $279.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2063.82B | $2063.82B | $1885.82B | $1736.99B | $1739.05B |
| Net Income | $366.95B | $366.95B | $321.67B | $259.36B | $285.78B |
| EBITDA | $494.46B | $494.46B | $433.59B | $370.67B | $415.70B |
| EPS | 13.57 | 13.57 | 11.89 | 9.59 | 10.56 |
| Gross Margin | 34.8% | 34.8% | 33.1% | 31.8% | 32.4% |
| Operating Margin | 18.9% | 18.9% | 18.3% | 17.3% | 21.4% |
| Net Margin | 17.8% | 17.8% | 17.1% | 14.9% | 16.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.08 | 0.09 | 0.10 |
| Current Ratio | 11.08 | 11.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $279.19B | $279.19B | $260.18B | $-22.09B | $17.25B |
| Returns | |||||
| ROE | 13.5% | 13.5% | 13.1% | 11.7% | 14.0% |
| Valuation | |||||
| P/E | 14.20 | 14.20 | 15.56 | 21.06 | 20.83 |
| EV/EBITDA | 9.12 | 9.12 | 9.15 | 12.23 | 12.80 |
| P/B | 2.05 | 2.05 | 2.03 | 2.46 | 2.91 |
| Growth & Yield | |||||
| Revenue Growth | 9.4% | 9.4% | 8.6% | -0.1% | — |
| EPS Growth | 14.1% | 14.1% | 24.0% | -9.2% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.4%
EPS terminal req.
$18.28
Spread vs growth
3.7%
5Y implied EPS CAGR
10.3%
EPS terminal req.
$22.12
Spread vs growth
3.9%
10Y implied EPS CAGR
10.1%
EPS terminal req.
$35.62
Spread vs growth
4.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.1%
Start / end P/E
14.4x → 16.9x
EPS bridge
11.89 → 13.57
Residual
+2.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.